Rubius Therapeutics

62 articles with Rubius Therapeutics

• Rubius Therapeutics to Participate at Upcoming Investor Conferences - Sep 08, 2020

  9/8/2020

  Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, announced that it will participate in the following investor conferences:

• Rubius Therapeutics Reports Second Quarter 2020 Financial Results and Positive Progress Across Pipeline

  8/10/2020

  Strong Momentum in Dosing Patients and Manufacturing Clinical Supply for  RTX-240 Phase 1/2 Solid Tumor Clinical Trial Investigational New Drug Application on Track by Year-End for RTX-321 for HPV-Positive Cancers

• Rubius Therapeutics to Announce Second Quarter 2020 Financial Results

  8/3/2020

  Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, announced plans to report second quarter 2020 financial results on Monday, August 10, 2020, before market open.

• 

  Clinical Catch-Up: June 29-July 3

  7/6/2020

  Heading into the 4th of July holiday in the U.S., there was still a fair amount of clinical trial news last week. Here’s a look.

• Rubius Therapeutics Provides Update on Clinical Trial Progress for its Lead Oncology Product Candidate RTX-240 and Announces Planned Leadership Transition

  6/30/2020

  Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, today announced that it has completed dosing of the first dose-escalation cohort with no observed adverse events to date in the Phase 1/2 clinical trial of RTX-240. RTX-240 is an allogeneic cellular therapy for the treatment of patients with relapsed/refracto

• Rubius Therapeutics Highlights Preclinical Data for RTX-321, a Red Cell Therapeutic™ Oncology Product Candidate for HPV-Positive Cancers, at the American Association of Cancer Research Virtual Annual Meeting II

  6/22/2020

  Rubius Therapeutics, Inc. announced the presentation of preclinical data supporting its lead artificial antigen-presenting cell program, RTX-321, for the potential treatment of human papillomavirus 16-positive cancers during the American Association for Cancer Research Virtual Annual Meeting II.

• Rubius Therapeutics to Present at Jefferies Virtual 2020 Healthcare Conference

  5/26/2020

  Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, announced that Pablo J. Cagnoni, M.D., chief executive officer, will participate in a fireside chat at the Jefferies Virtual 2020 Healthcare Conference on Tuesday, June 2, 2020, at 1:00 p.m. ET.

• Rubius Therapeutics to Present Preclinical Data for RTX-321, a Red Cell Therapeutic™ Oncology Product Candidate for HPV-Positive Cancers at the American Association of Cancer Research Annual Meeting

  5/15/2020

  Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, today announced that the Company plans to present preclinical data supporting its lead artificial antigen-presenting cell (aAPC) program, RTX-321, for the potential treatment of human papillomavirus (HPV) 16-positive cancers, during the American Association f

• Rubius Therapeutics Highlights Preclinical Data for RTX-321, a Red Cell Therapeutic™ Oncology Product Candidate for HPV-Positive Cancers, at the American Society of Gene & Cell Therapy 23rd Annual Meeting

  5/12/2020

  Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, today presented preclinical data supporting its lead artificial antigen-presenting cell (aAPC) program, RTX-321, for the potential treatment of HPV 16-positive tumors at the American Society of Gene and Cell Therapy 23rd Annual Meeting. The meeting is being he

• Rubius Therapeutics Reports First Quarter 2020 Financial Results and Provides Operational Update

  5/11/2020

  Completed Strategic Reprioritization of Pipeline to Focus on Oncology and Autoimmunity Dosed First Patient in Phase 1/2 Clinical Trial of RTX-240 for Advanced Solid Tumors Successfully Produced cGMP Clinical Supply of RTX-240 from Fully Owned Manufacturing Facility Strong Cash Position CAMBRIDGE, Mass., May 11, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an ent

• Rubius Therapeutics Announces Dosing of First Patient in Phase 1/2 Trial of RTX-240, an Allogeneic Cellular Therapy, for the Treatment of Solid Tumors

  5/7/2020

  Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, today announced that the first patient has been dosed in its Phase 1/2 clinical trial of RTX-240 for the treatment of patients with relapsed/refractory or locally advanced solid tumors. RTX-240 is an allogeneic, off-the-shelf Red Cell Therapeutic™ that is eng

• Rubius Therapeutics to Announce First Quarter 2020 Financial Results

  5/4/2020

  Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, announced plans to report first quarter 2020 financial results on Monday, May 11, 2020, before market open.

• Rubius Therapeutics Announces Preclinical Data from Red Cell Therapeutic Oncology Programs to be Presented at the ASGCT 23rd Annual Meeting

  4/29/2020

  Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, today announced that the company will present preclinical data from its oncology pipeline of Red Cell Therapeutics™ (RCTs) at the American Society of Gene and Cell Therapy (ASGCT) 23 rd Annual Meeting. The meeting is being held virtually from May 12 – 15, 2

• 

  Rubius Therapeutics Reprioritizes Pipeline for Cancer, Autoimmune Disorders

  3/13/2020

  Rubius Therapeutics is minimizing its focus on its rare disease pipeline and taking greater aim at developing treatments for cancer and autoimmune diseases.

• Rubius Therapeutics Reports Fourth Quarter and Full-Year 2019 Financial Results and Announces Strategic Focus on Oncology and Autoimmunity

  3/12/2020

  Rubius Therapeutics, Inc. today reported fourth quarter and full year 2019 financial results.

• Rubius Therapeutics to Report Fourth Quarter and Full-Year 2019 Financial Results and Host Webcast

  3/3/2020

  Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, today announced that it will report fourth quarter and full-year 2019 financial results and provide a business update on Thursday, March 12, 2020.

• 

  Clinical Catch-Up: January 27-31

  2/3/2020

  It was another busy week for clinical trial updates. Here’s a look.

• Rubius Therapeutics Announces First Patient Dosed in Phase 1b Trial of RTX-134 for the Treatment of Patients with Phenylketonuria

  1/30/2020

  Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, today announced that the first patient has been dosed in its Phase 1b trial of RTX-134, an allogeneic, off-the-shelf cellular therapy for the potential treatment of patients with phenylketonuria (PKU).

• Rubius Therapeutics Announces 2020 Objectives and Provides Operational Update at the 38th Annual J.P. Morgan Healthcare Conference

  1/13/2020

  RTX-240 Investigational New Drug Application for Cancer on File with U.S. Food and Drug Administration

• Rubius Therapeutics Appoints Internationally Recognized Autoimmunity and Translational Immunology Leader Laurence Turka, M.D., as Chief Scientific Officer

  1/8/2020

  Rubius Therapeutics, Inc. announced the appointment of Laurence Turka, M.D., as its first chief scientific officer, effective January 21, 2020.